May 17, 2020

Acceleron and Celegene work to better serve the anemia problem

Admin
2 min
Acceleron and Celegene work to better serve the anemia problem.jpg
Partnerships like the beneficial one between Acceleron and Celegeneaccount for a large number of successful pharma trials set to take center stage in 2...

Partnerships like the beneficial one between Acceleron and Celegene account for a large number of successful pharma trials set to take center stage in 2014. These two companies present an answer to the long-term problem of anemia and the lack of effective drugs in the current market to serve patients in need. 

Acceleron is set to receive a $7 million payment from its partner Celegene for its Phase 2 trial for the initiation of a Phase 2 clinical trial of sotatercept in patients on dialysis with end stage renal disease. The company is also eligible to receive future milestones of up to $360 million for the sotatercept program.

In the 1980s, this technology was used for treating anemia and maintaining its monopoly for over two decades. The giant of the anemia business is, of course, Amgen (AMGN). Amgen became the largest biotech company chiefly on the back of a drug it developed. A number of companies have tried, and failed, to knock Amgen out of that position throughout the years. But now an alliance of Celgene and Acceleron is taking another serious shot at the industry giant with sotatercept and ACE-536.

"Not many people know that several current members of Acceleron's management team, including CEO John Knopf, were bloodied in a court battle with Amgen. In the 1980s, as members of the Cambridge, MA-based Genetics Institute team they were at the losing end of a court fight over patents with Amgen, which was won, as usual, by Amgen. In the current reincarnation they have been extra careful to avoid giving another opportunity to Amgen's lawyers. Also, this time they have the backing of another powerful company, Celgene," says a source on the subject. 

"Sotatercept, Acceleron's lead drug, increases hemoglobin levels and the mass of red cells by a novel mechanism. It is not an EPO (erythropoietin)-based product, it does not bind the EPO receptor, but works on a pathway that is fundamentally distinct from EPO. Hemoglobin is the oxygen-carrying protein inside red blood cells. It gives red blood cells their red color. People with anemia do not have enough hemoglobin."

Share article

Jun 22, 2021

NeuTigers: edge AI in healthcare

edgecomputing
edgeAI
AI
prediction
3 min
We take a look at edge AI and how NeuTigers is driving this forward in healthcare

What is edge AI? 

Edge AI is essentially a combination of edge computing and artificial intelligence. Algorithms are processed locally - directly on a mobile device or server - rather than in the cloud. This reduces cost, computing power and energy requirements. There are also claims that edge AI is so fast it is possible to reach near real-time analytics

Edge AI devices include smart speakers, smart phones, laptops, robots, self-driven cars, drones, and surveillance cameras that use video analytics. 

Who is NeuTigers? 

NeuTigers is a spin-off company from Princeton University, formed in 2018 to apply edge AI and machine learning to solve challenges in healthcare, energy, productivity, and security. 

With offices in Princeton, NJ, the company is based at one of the top AI accelerator programs of FutureLabs in New York, and has also established a subsidiary in Nice, France.

How is NeuTigers applying edge AI to healthcare? 

The NeuTigers AI Technology Stack uses deep  neural networks that mimic how the human brain perceives and interprets the world. The company has developed the StarDeepTM Smart Health Platform for health monitoring and biomedical imaging, to improve the accuracy and speed of diagnosing diseases. 

NeuTigers say the platform has the potential to monitor and screen for thousands of conditions,  when used in combination with medical devices and  smart sensors already deployed in healthcare settings. 

Are there any real world examples? 

In January NeuTigers launched CovidDeep, a tool that predicts COVID-19 with more than 90% accuracy, using physiological data from a wristband along with blood pressure and blood oxygen readings. It then analyses the data and gives a prediction within two minutes. 

This week NeuTigers announced a new study to detect the early signs of  complications with sickle cell anaemia.  Conducted at a hospital in Paris, the research will begin by looking at changes to skin response, heart beat, sleep and temperature to predict an acute episode of sickle cell anaemia, and how this impacts on the patients’ disease conditions and quality of life. 

The second phase of the project is to expand with prospective studies across different sites in EU, Africa  and the US to explore the models' accuracy and clinical effectiveness. 

They say...

Adel Laoui, CEO and founder of NeuTigers, says: “The best way to deal with a crisis is to avoid it happening in the first place. We are now entering a new era where medical early warning systems have become a reality. 

“We are excited at the possibility of deploying a technology that can save lives of patients dealing with sickle cell anaemia. The potential of the StarDeep platform to dramatically improve patient outcomes while slashing some of the highest costs of healthcare makes it one of the most exciting developments in preventative personal medicine.”

Share article